---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-26-000007"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T19:40:58.593973+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Caribou Biosciences FY2025 net loss $148.1M; cash $142.8M funds into 2H 2027

## Summary
- GAAP net loss FY2025 $148.1M ($1.59/sh) vs $149.1M ($1.65) prior year; non-GAAP loss $126.8M excluding $21.3M impairment.
- Revenue FY2025 $11.2M (vs $10.0M in 2024); R&D expenses down to $109.4M due to workforce reduction and pipeline prioritization.
- Cash, equivalents, marketable securities $142.8M at Dec 31, 2025, down from $249.4M; funding expected into 2H 2027; exploring options for pivotal trial.
- Vispa-cel (CB-010) phase 1 data shows efficacy on par with autologous CAR-T; FDA engagement for pivotal trial design; longer follow-up expected 2026.
- CB-011 dose expansion initiated for multiple myeloma; initial data expected in 2026.

## SEC filing metadata
- accession: 0001619856-26-000007
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985626000007/0001619856-26-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985626000007/crbu-20260305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-26-000007
- JSON: https://secwatch.observer/filing/0001619856-26-000007.json
- Plain text: https://secwatch.observer/filing/0001619856-26-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.